Oncology
Drug combo cuts prostate cancer death risk by over 40 percent
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Vaccine Therapy Progress for Brain Tumors
AI에 의해 보고됨 사실 확인됨
Vaccine therapy for malignant glioma is advancing, with calls for expedited approvals to treat this aggressive brain cancer. The approach has potential to save lives and is part of efforts for rare disease treatments. Early results indicate effectiveness without traditional chemo or radiation.
Study confirms rise in cancer cases among adults under 50
A new international analysis reveals an increase in six types of cancer among adults aged 20 to 49 in 42 countries, mainly linked to obesity and sedentarism. Except for colorectal cancer, these tumors are also rising in those over 50. Experts urge investigating causes and enhancing prevention.
Summit's Lung Cancer Drug Progress
Summit's new drug for lung cancer demonstrated promising results in recent assessments. This development is part of ongoing biotech advancements in oncology. It was reported alongside other health innovations.